Tech Company Financing Transactions
AusperBio Funding Round
On 8/28/2026, AusperBio raised $120 million in Series C financing from CDH Investments, Hankang Capital and InnoPinnacle Fund.
Transaction Overview
Company Name
Announced On
8/28/2026
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to support the continued development of AHB-137, including its Phase 3 registrational program and commercialization readiness, accelerate the development of AHB-171, advance new combination approaches for CHB, and expand its pipeline of targeted oligonucleotide therapeutics.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3 E. 3rd Ave 200
San Mateo, CA 94401
USA
San Mateo, CA 94401
USA
Phone
Website
Email Address
Overview
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo� ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, and to transform patient lives.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/27/2026: Cyclic Materials venture capital transaction
Next: 8/28/2026: Xanadu venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








